IL150768A0 - Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers - Google Patents

Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers

Info

Publication number
IL150768A0
IL150768A0 IL15076800A IL15076800A IL150768A0 IL 150768 A0 IL150768 A0 IL 150768A0 IL 15076800 A IL15076800 A IL 15076800A IL 15076800 A IL15076800 A IL 15076800A IL 150768 A0 IL150768 A0 IL 150768A0
Authority
IL
Israel
Prior art keywords
trilostane
compounds
cancers
prostate
breast
Prior art date
Application number
IL15076800A
Other languages
English (en)
Inventor
George Margetts
John Puddefoot
Gavin Paul Vinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL150768A0 publication Critical patent/IL150768A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
IL15076800A 2000-01-18 2000-07-25 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers IL150768A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0000984A GB2345851B (en) 2000-01-18 2000-01-18 A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
PCT/GB2000/002858 WO2001053321A2 (en) 2000-01-18 2000-07-25 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers

Publications (1)

Publication Number Publication Date
IL150768A0 true IL150768A0 (en) 2003-02-12

Family

ID=9883801

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15076800A IL150768A0 (en) 2000-01-18 2000-07-25 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers
IL150768A IL150768A (en) 2000-01-18 2002-07-16 Use of trilostane and its derivatives for the preparation of pharmaceutical compositions, optionally in combination with tamoxifen or raloxifene, for the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150768A IL150768A (en) 2000-01-18 2002-07-16 Use of trilostane and its derivatives for the preparation of pharmaceutical compositions, optionally in combination with tamoxifen or raloxifene, for the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers

Country Status (11)

Country Link
EP (1) EP1255553B1 (xx)
JP (1) JP2003520803A (xx)
AT (1) ATE484282T1 (xx)
AU (1) AU785439B2 (xx)
CA (1) CA2395481C (xx)
DE (1) DE60045111D1 (xx)
GB (1) GB2345851B (xx)
IL (2) IL150768A0 (xx)
NZ (1) NZ520350A (xx)
WO (1) WO2001053321A2 (xx)
ZA (1) ZA200206507B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361642A (en) * 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
GB2375958B (en) * 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
GB2421183A (en) * 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
JP5544458B2 (ja) 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
SG2014008171A (en) 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US9351979B2 (en) 2012-12-19 2016-05-31 Ampio Pharmaceuticals, Inc. Methods of treatment of diseases
FR3131285A1 (fr) 2021-12-23 2023-06-30 Kis Installation de distribution de boissons dans des recipients notamment de type canette

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5995300A (ja) * 1982-11-02 1984-06-01 スタ−リング・ドラッグ・インコ−ポレ−テッド コントロ−ルされた粒度の２−シアノ−４，５−エポキシ−３−オキソ−ステロイド類およびそれらの組成物
GB8404980D0 (en) * 1984-02-25 1984-03-28 Sterwin Ag Steroid compound
DE3720420A1 (de) * 1987-06-16 1988-12-29 Schering Ag Progesteronsynthesehemmer und antigestagene zur geburtseinleitung oder fuer den schwangerschaftsabbruch
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases

Also Published As

Publication number Publication date
ZA200206507B (en) 2005-01-13
WO2001053321A2 (en) 2001-07-26
CA2395481A1 (en) 2001-07-26
EP1255553A2 (en) 2002-11-13
IL150768A (en) 2007-10-31
NZ520350A (en) 2004-05-28
AU785439B2 (en) 2007-05-31
AU6171400A (en) 2001-07-31
DE60045111D1 (de) 2010-11-25
JP2003520803A (ja) 2003-07-08
GB2345851A (en) 2000-07-26
CA2395481C (en) 2008-11-18
WO2001053321A3 (en) 2002-02-28
ATE484282T1 (de) 2010-10-15
GB2345851B (en) 2004-05-26
EP1255553B1 (en) 2010-10-13
GB0000984D0 (en) 2000-03-08

Similar Documents

Publication Publication Date Title
Meikle et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system
Tyrrell et al. A randomised comparison of ‘Casodex’TM (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
Denmeade et al. A history of prostate cancer treatment
WO2001086307A3 (en) Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
IL150768A0 (en) Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers
Van Steenbrugge et al. Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82)
Davey Brain metastases
Zhu Palliative radiotherapy for painful bone metastases: short-course or long-course?
McNeill et al. The effect of epidermal growth factor, transforming growth factor and breast tumour homogenates on the activity of oestradiol 17β hydroxysteroid dehydrogenase in cultured adipose tissue
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
d'Istria et al. Receptors for sex hormones in the skin of the amphibia
Ataee et al. The role of melatonin and melatonin receptors in pharmacology and pharmacotherapy of cancer
Ahmad et al. Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice
Ren et al. Combined treatment for pain from bone metastases in patients with prostate cancer
De Santis et al. Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?
Bertetto et al. Quality of life studies and genito-urinary tumors
Schmidt The patient, disease status, and treatment options for prostate cancer: stages D1 and D2
Pincus Recent Progress in Hormone Research: The Proceedings of the Laurentian Hormone Conference
Landström et al. Dose/response study of the effects of oestrogens on tumour growth and morphology in the Dunning R3327 prostatic adenocarcinoma
van Steenbrugge et al. Hormonal and growth factor manipulation of human prostate cancer in the nude mouse model
WO1998022623A3 (en) Cdna collections encoding proteins regulated during programmed cell death, and methods of use thereof
WeiJie et al. Research advances in 125 radioactive seed implantation for treatment of unresectable pancreatic cancer
Joshi et al. 107. Progestin-dependent proteins in the human endometrium
Forbes Oestrogen receptors: quality or quantity
Mohla et al. 106. The effects of estradiol in vivo of purified estradiol-estrophilin complexes in vitro on binding and template activity of uterine chromatin and its fractions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed